Harmony Biosciences Quarterly Balance Sheet
NASDAQ: HRMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Harmony Biosciences financial position
As of Jun 30, 2026, Harmony Biosciences reported total assets of $1.37 billion, up 23.9% from a year earlier against total liabilities of $373.8 million. Shareholders' equity stood at $999.2 million, or 72.8% of assets. The company held $549.8 million in cash and equivalents against $154.0 million of debt, a net cash position of $395.8 million.
The current ratio (current assets divided by current liabilities) was 3.48, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.15.
Summary generated from market data by MetaCap's automated system. Methodology
Harmony Biosciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 549.77M | 589.40M | 752.50M | 647.00M | 546.05M | 489.00M | 453.00M | 387.37M | 317.30M | 332.98M | 311.66M | 324.60M |
| Short-Term Investments | 118.02M | 51.52M | 22.84M | 25.58M | 19.22M | 17.95M | 14.19M | 23.11M | 29.61M | 39.37M | 41.80M | 46.07M |
| Receivables | 111.00M | 108.22M | 96.79M | 100.65M | 92.98M | 105.97M | 83.03M | 81.50M | 83.16M | 79.72M | 74.14M | 67.26M |
| Inventory | 6.36M | 5.28M | 5.36M | 6.88M | 6.10M | 6.38M | 7.20M | 6.92M | 5.64M | 5.86M | 5.36M | 5.09M |
| Total Current Assets | 814.33M | 778.82M | 907.01M | 838.80M | 691.35M | 642.69M | 579.25M | 522.40M | 458.34M | 479.50M | 451.07M | 463.00M |
| Property, Plant & Equipment | — | — | — | 1.44M | 1.38M | 1.38M | 1.26M | 750.00K | 754.00K | 213.00K | 371.00K | 428.00K |
| Intangible Assets | 77.50M | 83.46M | 89.42M | 95.38M | 101.34M | 107.30M | 113.26M | 119.22M | 125.19M | 131.15M | 137.11M | 143.07M |
| Long-Term Investments | 294.67M | 229.56M | 107.13M | 105.83M | 107.01M | 103.25M | 108.87M | 94.22M | 87.18M | 81.24M | 72.17M | 67.70M |
| Total Assets | 1.37B | 1.27B | 1.27B | 1.21B | 1.11B | 1.06B | 999.20M | 928.13M | 858.38M | 846.99M | 811.45M | 777.77M |
| Accounts Payable | 21.68M | 28.60M | 17.69M | 26.34M | 28.30M | 17.46M | 13.74M | 10.53M | 22.68M | 15.14M | 17.73M | 6.54M |
| Short-Term Debt | 20.00M | 20.00M | 20.00M | 20.00M | 18.75M | 17.50M | 16.25M | 15.00M | 15.00M | 15.00M | 15.00M | 15.00M |
| Total Current Liabilities | 234.07M | 217.34M | 252.13M | 223.40M | 180.13M | 175.12M | 175.08M | 161.28M | 146.58M | 154.25M | 163.78M | 112.41M |
| Long-Term Debt | 133.96M | 138.81M | 143.66M | 148.51M | 153.34M | 158.18M | 163.02M | 167.85M | 171.42M | 175.00M | 178.57M | 182.13M |
| Total Liabilities | 373.84M | 361.48M | 401.41M | 373.10M | 334.93M | 335.01M | 340.05M | 331.33M | 319.80M | 331.59M | 344.46M | 296.43M |
| Shareholders' Equity | 999.24M | 910.35M | 870.22M | 835.12M | 773.08M | 720.52M | 659.15M | 596.80M | 538.58M | 515.39M | 466.99M | 481.33M |
| Retained Earnings | 268.82M | 193.39M | 160.90M | 138.42M | 87.55M | 47.78M | 2.22M | -47.26M | -93.35M | -104.94M | -143.28M | -169.88M |
| Total Debt | 153.96M | 158.81M | 163.66M | 168.51M | 172.09M | 175.68M | 179.27M | 182.85M | 186.42M | 190.00M | 193.57M | 197.13M |
| Net Cash (Debt) | 513.83M | 482.10M | 611.68M | 504.07M | 393.18M | 331.27M | 287.92M | 227.63M | 160.49M | 182.35M | 159.89M | 173.54M |
| Shares Outstanding | 58.12M | 57.87M | 57.73M | 57.60M | 57.54M | 57.39M | 57.14M | 57.03M | 56.83M | 56.79M | 56.77M | 58.57M |
This table shows 12 quarterly periods of Harmony Biosciences's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow HRMY's reporting calendar. What is a balance sheet?